《Tris(dibenzylideneacetone)dipalladium(0) (Tris DBA) Abrogates Tumor Progression in Hepatocellular Carcinoma and Multiple Myeloma Preclinical Models by Regulating the STAT3 Signaling Pathway》 was written by Arora, Loukik; Mohan, Chakrabhavi Dhananjaya; Yang, Min Hee; Rangappa, Shobith; Deivasigamani, Amudha; Kumar, Alan Prem; Kunnumakkara, Ajaikumar B.; Garg, Manoj; Chinnathambi, Arunachalam; Alharbi, Sulaiman Ali; Alahmadi, Tahani Awad; Rangappa, Kanchugarakoppal S.; Hui, Kam Man; Sethi, Gautam; Ahn, Kwang Seok. Computed Properties of C51H42O3Pd2This research focused ontri dibenzylideneacetone dipalladium xenograft signaling inhibitor abrogate tumor progression; SHP2; STAT3 signaling inhibitor; Tris DBA; orthotopic; xenograft. The article conveys some information:
Simple Summary: STAT3 is a major oncogenic transcription factor that is constitutively activated in many types of human cancers, including hepatocellular carcinoma (HCC) and multiple myeloma (MM). Many STAT3 inhibitors have gained momentum in clin. trials towards the treatment of various cancers. In the present study, we have investigated the STAT3 inhibitory efficacy of Tris DBA, a palladium-based compound, in HCC and MM cancer cells and preclin. cancer models. Tris(dibenzylideneacetone)dipalladium(0) (Tris DBA) abrogated the STAT3 signaling pathway in both models by elevating the expression of SHP2. Functionally, Tris DBA inhibited cell proliferation, migration, invasion, and regressed tumor metastasis. Although many studies propose Tris DBA as a modulator of MAPK, Akt, phospho-S6 kinase, and N-myristoyltransferase-1, we have comprehensively demonstrated for the first time that Tris DBA is an inhibitor of STAT3 signaling in preclin. cancer models. These results support the consideration of Tris DBA in clin. trials in translational relevance. Abstract: STAT3 is an oncogenic transcription factor that controls the expression of genes associated with oncogenesis and malignant progression. Persistent activation of STAT3 is observed in human malignancies, including hepatocellular carcinoma (HCC) and multiple myeloma (MM). Here, we have investigated the action of Tris(dibenzylideneacetone) dipalladium 0 (Tris DBA) on STAT3 signaling in HCC and MM cells. Tris DBA decreased cell viability, increased apoptosis, and inhibited IL-6 induced/constitutive activation of STAT3, JAK1, JAK2, and Src in HCC and MM cells. Tris DBA downmodulated the nuclear translocation of STAT3 and reduced its DNA binding ability. It upregulated the expression of SHP2 (protein and mRNA) to induce STAT3 dephosphorylation, and the inhibition of SHP2 reversed this effect. Tris DBA downregulated the expression of STAT3-driven genes, suppressed cell migration/invasion. Tris DBA significantly inhibited tumor growth in xenograft MM and orthotopic HCC preclin. mice models with a reduction in the expression of various prosurvival biomarkers in MM tumor tissues without displaying significant toxicity. Overall, Tris DBA functions as a good inhibitor of STAT3 signaling in preclin. HCC and MM models.Tris(dibenzylideneacetone)dipalladium(0)(cas: 51364-51-3Computed Properties of C51H42O3Pd2) was used in this study.
Tris(dibenzylideneacetone)dipalladium(0)(cas: 51364-51-3) is used in the preparation of semiconducting polymers processed from nonchlorinated solvents into high performance thin film transistors.Computed Properties of C51H42O3Pd2 It is also used in the synthesis of polymer bulk-heterojunction solar sells as a semiconductor.
Referemce:
Metal catalyst and ligand design,
Ligand Template Strategies for Catalyst Encapsulation – NCBI